Regional map of medicines
Peru
22,157people on antiretroviral treatment (2013)
59 %treatment coverage (2013)
Mixedhealth insurance model
Antiretroviral medicines (2013)
| Medicine | Unit price (US$) | Cost per person per year (US$) | Patent in force | Data protection | Monopoly | Possible savings per person per year (US$) |
|---|---|---|---|---|---|---|
| Abacavir 300 mg | 0.68 | 493 | Yes | No | No | 323 |
| Atazanavir 300 mg | 12.68 | 4,630 | Yes | No | Yes | 4,399 |
| Etravirina 100 mg | 6.12 | 8,941 | Yes | No | Yes | 8,473 |
| Lopinavir Ritonavir 200mg - 50 mg | 0.41 | 596 | Yes | No | No | 227 |
| Raltegravir 400 mg | 7.34 | 5,361 | No | No | Yes | 3,609 |
| Emtricitabina Tenofovir 200mg - 300 mg | — | — | — | — | — | — |
| Maraviroc 300 mg | — | — | — | — | — | — |
| Emtricitabina-tenofovir-efavirenz 600 mg - 300 mg - 200 mg | — | — | — | — | — | — |
Epidemiological data
| Year | People on treatment | People without treatment | Treatment coverage |
|---|---|---|---|
| 2013 | 22,157 | 37,000 | 59 % |
Health coverage
- Insurance model
- Mixed (subsidized and contributive)
- Provision of antiretrovirals
- Free of charge. Provided by each sub-system except private sector
- Procurement of antiretrovirals
- Centralized, except for private sector
The data were provided by RedLAM member organizations at the time; each table shows the year.